ERCC1

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Z. C. Xu, Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., Xu, L., Xu, Z. C., Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., and Xu, L., “ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer”, vol. 15, p. -, 2016.

This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscle-invasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. The genotypes of patients were determined by PCR amplification of genomic DNA followed by restriction enzyme digestion. Positive responses were categorized as complete and partial responses.

Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression

C. Y. Li, Ren, Y. J., Li, Y. D., Li, C. Y., Ren, Y. J., and Li, Y. D., “Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression”, vol. 15, p. -, 2016.

SNX-2112 is a potential molecular targeted therapeutic drug against esophageal cancer (EC). However, its exact mechanism of action remains to be explained. The aim of this study was to investigate the effect of SNX-2112 on excision repair cross- complementing 1 (ERCC1), epidermal growth factor receptor (EGFR), and p53, to elucidate the mechanism of action of SNX-2112 on EC. Fresh tumor sections were surgically obtained from 65 patients with EC, and the expression of ERCC1, EGFR, and p53 was determined by immunohistochemical staining.

Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer

D. L. Zheng, Tang, G. D., Chen, Y. N., Zhang, T., Qin, M. B., Zheng, D. L., Tang, G. D., Chen, Y. N., Zhang, T., Qin, M. B., Zheng, D. L., Tang, G. D., Chen, Y. N., Zhang, T., and Qin, M. B., “Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer”, vol. 15, p. -, 2016.

We conducted a prospective study to investigate whether ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 gene polymorphisms could serve as potential biomarkers for the prognosis of gastric cancer. Between January 2010 and December 2012, 246 patients with pathologically proven gastric cancer who were receiving platinum-based chemotherapy were recruited from the First Affiliated Hospital of Guangxi Medical University.

Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer

M. G. He, Zheng, K., Tan, D., Wang, Z. X., He, M. G., Zheng, K., Tan, D., Wang, Z. X., He, M. G., Zheng, K., Tan, D., and Wang, Z. X., “Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer”, vol. 15, p. -, 2016.

We conducted a study to investigate the association between ERCC1 (rs3212986) and ERCC2 (rs13181) gene polymorphisms and the risk of pancreatic cancer in a Chinese population. A total of 217 pancreatic cancer patients and 244 control subjects were recruited from the Nuclear Industry 215 Hospital of Shaanxi Province between February 2013 and December 2014. Genomic DNA was extracted from peripheral blood samples using a TIANamp Blood DNA Kit (Tiangen, Beijing, China) according to the manufacturer’s instructions.

Subscribe to ERCC1